̽»¨ºÏ¼¯

̽»¨ºÏ¼¯ today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.

̽»¨ºÏ¼¯ and Humanigen today announced the expansion of their relationship, under which ̽»¨ºÏ¼¯ will provide development, manufacturing and commercialization services for lenzilumab.

̽»¨ºÏ¼¯ today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

̽»¨ºÏ¼¯ today announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.

Moderna and ̽»¨ºÏ¼¯ today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at ̽»¨ºÏ¼¯â€™s biologics facility in Bloomington, Indiana.

̽»¨ºÏ¼¯ today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.

̽»¨ºÏ¼¯ Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

̽»¨ºÏ¼¯ today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.

̽»¨ºÏ¼¯ today announced that John Chiminski, Chair and Chief Executive Officer, will join other R&D leaders to present during BIO Digital, which will take place on June 8 – 12, 2020.